Androgen receptor antisense oligonucleotide AZD5312

Drug Overview

The medication known as androgen receptor antisense oligonucleotide AZD5312 (also identified as ISIS-ARRx or ISIS 560131) is a high-precision experimental therapy designed to treat advanced, treatment-resistant prostate cancer. Unlike traditional hormonal therapies that block testosterone from binding to its receptor, AZD5312 is a “genetic silencer.” It targets the blueprints of the androgen receptor (AR) inside the cell, stopping the receptor from being built in the first place.

In clinical oncology, AZD5312 is classified as a Generation-2.5 Antisense Oligonucleotide (ASO). It is a synthetic string of genetic material engineered to bypass the common ways cancer cells become resistant to standard drugs like Enzalutamide or Abiraterone. By “erasing” the AR protein entirely, it aims to shut down the growth engine of the tumor at its source.

• Generic Name: Androgen receptor antisense oligonucleotide AZD5312.
• Drug Class: Antisense Oligonucleotide (ASO) / RNA-targeted Therapy.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of 2026, it is in Phase I/II clinical trials. It is not yet approved for general public prescription and is available only through participation in approved research studies.

What Is It and How Does It Work? (Mechanism of Action)

AZD5312 is a “Smart Genetic Drug” that functions as a molecular eraser. To understand its action at the molecular level, we must look at the “Central Dogma” of biology: DNA makes mRNA, and mRNA makes protein.

The AR Silencing Strategy

In advanced prostate cancer, cells often produce too much AR protein or create “mutant versions” that don’t need hormones to grow. Standard drugs cannot block these mutant versions because they are missing the “docking port” where the drug would normally attach. AZD5312 solves this by targeting the mRNA—the intermediate messenger—before the protein is even formed.

Molecular Level Mechanisms

1. Hybridization: AZD5312 is a “mirror image” of a specific section of the AR mRNA. Once it enters the cancer cell, it seeks out and binds to that mRNA, creating a double-stranded DNA-RNA hybrid.
2. RNase H Recruitment: The human body has an enzyme called RNase H that acts like a genetic security guard. When it sees this “unnatural” hybrid, it immediately arrives and shreds the mRNA.
3. Protein Depletion: Because the mRNA is destroyed, the cell’s “factory” (the ribosome) never receives the instructions to build the Androgen Receptor. The total amount of AR protein in the cell drops significantly.
4. Inducing Apoptosis: Without the AR protein to signal growth and survival, the prostate cancer cell loses its structural integrity and enters apoptosis (programmed cell death). This works even if the cell has developed resistance to other hormonal treatments.

FDA Approved Clinical Indications

AZD5312 is an investigational agent and is currently available only through enrollment in clinical trials for the following:

Oncological Uses (In Clinical Trials):

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has progressed despite surgical or chemical castration.
• Anti-Hormone Resistant Cancer: Specifically for patients who have relapsed while taking second-generation drugs like Enzalutamide or Abiraterone.
• Advanced Solid Tumors (AR-Dependent): Investigated in rare cases of breast, bladder, and salivary duct cancers where the Androgen Receptor may be driving the disease.

Non-oncological Uses:

• There are currently no non-oncological uses for AZD5312.

Dosage and Administration Protocols

In Phase I clinical trials, AZD5312 is administered by a medical professional in a hospital or clinic setting.

Clinical Efficacy and Research Results

Recent data from 2024 to early 2026 highlights the potential of AZD5312 to tackle “splice variant” resistance.

• Targeting Splice Variants: Research confirms that AZD5312 can lower levels of AR-V7, a specific mutated version of the receptor that is notorious for causing resistance to all known hormonal drugs.
• PSA Response: In early dose-expansion studies, a subset of patients with heavily pre-treated prostate cancer showed a measurable decline in PSA (Prostate-Specific Antigen) levels, indicating the drug was successfully reaching and affecting the tumor.
• Combination Synergy: Preclinical data suggests that AZD5312 is much more effective when used with AKT inhibitors (like Capivasertib). This combination prevents the cancer from switching to a “backup” growth pathway.

Safety Profile and Side Effects

As an antisense oligonucleotide, AZD5312 has side effects related to how the body processes these small genetic strands, as well as its effects on the liver and blood.

Common Side Effects (>10%):

• Fatigue: The most frequently reported symptom, ranging from mild to moderate.
• Injection Site Reactions: Temporary redness or discomfort at the IV site.
• Fever and Chills: Mild “flu-like” symptoms shortly after the infusion.
• Nausea: Usually manageable with standard medication.

Serious Adverse Events:

• Thrombocytopenia: A drop in the number of platelets, which can increase the risk of bruising or bleeding.
• Hepatotoxicity: Temporary elevation of liver enzymes (ALT/AST).
• Renal Stress: Small genetic strands can sometimes affect kidney function, requiring regular monitoring.
• Black Box Warning: There is currently no FDA Black Box Warning for AZD5312.
• Management Strategies: Platelet levels and liver function are checked via blood tests every 1–2 weeks. If levels drop too low, the dose is held until the body recovers.

Research Areas

In the realm of Regenerative Medicine and Stem Cell Research, AZD5312 is being used as a “Molecular Tool” to study cell fate. Because it can “turn off” the Androgen Receptor so precisely, scientists use it to see how prostate stem cells decide to become either healthy prostate tissue or cancerous cells. This research aims to understand how to “regenerate” a healthy prostate environment by selectively silencing the genes that drive the transition into cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Complete Blood Count (CBC): To ensure platelets are at a safe level for treatment.
• Liver Function Tests (LFTs): To establish a baseline for hepatic health.
• Tumor Biopsy/Genetic Screening: Often required to confirm the presence of AR-driven disease.

Precautions During Treatment:

• Bleeding Risk: Report any unusual bruising, nosebleeds, or red spots on the skin (petechiae) immediately.
• Liver Health: Avoid heavy alcohol consumption while on this drug to minimize stress on the liver.

“Do’s and Don’ts” List:

• DO keep all appointments for blood draws, as monitoring your platelets is the “safety net” for this drug.
• DO drink plenty of water on the day of your infusion to help your kidneys.
• DON’T take any new over-the-counter blood thinners (like high-dose Aspirin) without asking your oncologist.
• DON’T ignore a sudden fever; while often a side effect, it should always be evaluated by your medical team.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. AZD5312 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.